Trial · NCT07529938
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 | Baseline to Week 30 | Change from baseline in resting left ventricular outflow tract (LVOT) peak gradient measured by Doppler echocardiography (unit: mmHg). Higher values indicate greater obstruction. |
| Secondary | Change in Valsalva-Induced Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 | Baseline to Week 30 | Change from baseline in LVOT peak gradient induced by the Valsalva maneuver measured by Doppler echocardiography (unit: mmHg). Higher values indicate greater obstruction. |
| Secondary | Proportion of Participants with Improvement in New York Heart Association (NYHA) Functional Classification at Week 30 | Baseline to Week 30 | Proportion of participants achieving at least one class improvement in New York Heart Association (NYHA) functional classification compared with baseline. NYHA class ranges from I to IV, where higher classes indicate worse functional status. |
| Secondary | Change in N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Levels at Week 30 | Baseline to Week 30 | Change from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (unit: pg/mL). Higher values indicate worse cardiac function. |
| Secondary | Change in High-Sensitivity Cardiac Troponin I (hs-cTnI) Levels at Week 30 | Baseline to Week 30 | Change from baseline in high-sensitivity cardiac troponin I (hs-cTnI) levels (unit: ng/L). Higher values indicate greater myocardial injury. |
| Secondary | Change in Left Ventricular Ejection Fraction (LVEF) at Week 30 | Baseline to Week 30 | Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiography (unit: %). Higher values indicate better cardiac systolic function. |
| Secondary | Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 30 | Baseline to Week 30 | Change from baseline in tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography (unit: mm). Higher values indicate better right ventricular function. |
| Secondary | Incidence of Adverse Events | Up to Week 30 | Number and proportion of participants experiencing any adverse events. |
| Secondary | Incidence of Serious Adverse Events | Up to Week 30 | Number and proportion of participants experiencing serious adverse events. |
| Secondary | Incidence of Treatment Discontinuation Due to Adverse Events | Up to Week 30 | Number and proportion of participants who discontinued treatment due to adverse events. |
| Secondary | Incidence of Left Ventricular Ejection Fraction Reduction Below 50% | Up to Week 30 | Number and proportion of participants with LVEF \<50% during treatment. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07529938/registered